Annual report pursuant to Section 13 and 15(d)

Basis of Presentation and Significant Accounting Policies (Details Narrative)

v3.20.4
Basis of Presentation and Significant Accounting Policies (Details Narrative)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
USD ($)
Segment
Dec. 31, 2019
USD ($)
Jan. 02, 2020
USD ($)
Jan. 02, 2019
USD ($)
Dec. 31, 2018
USD ($)
Number of operating segment | Segment 1        
Primary operating account balance $ 33,010 $ 7,418      
Cash uninsured amount 50        
Operating lease right-of-use assets 498 677      
Operating lease liabilities 523 700      
Goodwill 19,092 19,092     $ 65,195
Impairment in goodwill 46,103      
Collaboration revenue 2,014 6,564      
Intellectual Property [Member]          
Research and development in process 1,779 1,838      
Program expense reimbursements 235 358      
Collaboration revenue   4,368      
ASC 842 [Member]          
Operating lease right-of-use assets     $ 833 $ 833  
Operating lease liabilities     $ 833 $ 833  
Merck Sharp & Dohme Corp [Member]          
Accounts receivable related party $ 556 644      
Merck Sharp & Dohme Corp [Member] | Customer One [Member] | Customer Concentration Risk [Member] | Revenue and Receivables [Member]          
Revenue and receivable percentage 100.00%        
U.S. Financial Institutions One [Member]          
Cash FDIC insured limits $ 250 250      
U.S. Financial Institutions Two [Member]          
Cash FDIC insured limits $ 250 $ 250